Related Experiment Video
Updated: May 28, 2026
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
Discovery of a Small-Molecule Inhibitor Targeting the ELF3-HSP27 Interaction to Suppress Breast Cancer Progression
Yi Liu1, Sehyun Jung1, Soo-Yeon Hwang1
1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Abstract:
Background: Breast cancer remains a leading cause of cancer-related mortality in women, largely due to metastasis and treatment resistance. ELF3, an ETS transcription factor, has been linked to cancer progression; however, the mechanisms regulating its activity remain incompletely understood. Methods: ELF3 expression and its association with patient survival were analyzed using GEO datasets and the Kaplan-Meier Plotter platform. Functional studies were performed using ELF3 knockdown in breast cancer cell lines, followed by WST-1 assays and crystal violet staining. Protein-protein interactions were evaluated using co-expression analysis, immunofluorescence, split luciferase complementation, GST pull-down, and yeast two-hybrid assays. Cycloheximide chase assays were conducted to assess ELF3 protein stability. A panel of small molecules was screened to identify inhibitors of the ELF3-HSP27 interaction, and a lead compound was further validated using biochemical and functional assays. Antitumor activity was evaluated in a xenograft mouse model. Results: High ELF3 expression was associated with poorer overall survival in breast cancer patients. HSP27 was identified as a binding partner that stabilizes ELF3 protein, thereby promoting breast cancer cell proliferation. A novel small-molecule inhibitor disrupting the ELF3-HSP27 interaction suppressed cancer cell growth in vitro and reduced tumor growth in vivo. Conclusions: The ELF3-HSP27 interaction represents a previously unrecognized contributor to breast cancer progression, and its disruption provides a promising therapeutic strategy.
Insights
High ELF3 expression drives breast cancer progression by interacting with HSP27. Inhibiting this interaction shows promise as a new therapeutic strategy for breast cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer is a major cause of female mortality, often driven by metastasis and treatment resistance.
- The precise mechanisms governing the activity of the ETS transcription factor ELF3 in cancer progression are not fully understood.
Purpose of the Study:
- To investigate the role of ELF3 in breast cancer.
- To identify ELF3-interacting proteins and elucidate their function in breast cancer.
- To explore therapeutic strategies targeting the ELF3 pathway.
Main Methods:
- Analysis of ELF3 expression in patient data (GEO datasets, Kaplan-Meier Plotter).
- Functional assays (cell proliferation, knockdown studies) in breast cancer cell lines.
- Protein-protein interaction studies (co-expression, immunofluorescence, split luciferase, GST pull-down, yeast two-hybrid).
- Drug screening and validation of ELF3-HSP27 interaction inhibitors in vitro and in vivo.
Main Results:
- Elevated ELF3 expression correlates with reduced overall survival in breast cancer patients.
- Heat Shock Protein 27 (HSP27) was identified as a key binding partner that stabilizes ELF3, enhancing breast cancer cell proliferation.
- A novel small-molecule inhibitor targeting the ELF3-HSP27 interaction demonstrated efficacy in suppressing cancer cell growth and tumor progression.
Conclusions:
- The ELF3-HSP27 interaction is a novel factor contributing to breast cancer progression.
- Disrupting the ELF3-HSP27 interaction presents a potential new therapeutic avenue for breast cancer treatment.
